Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
BNT324-01
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- NCT06892548 ↗
- Recruiting
- BioNTech SE
- Standard
We haven't built an HCP commentary report on BNT324-01 (BNT324 and BNT327 in Advanced Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BNT324-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Advanced Lung Cancer
- Interventions
- BNT324; BNT327
- Arms
- Part 1 - BNT324 + BNT327 combination therapy · Experimental
- Part 2 - Cohort 1: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327 · Experimental
- Part 2 - Cohort 2: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327 · Experimental
- Part 2 - Cohort 3: RP2D of BNT324 + BNT327 · Experimental
- Part 2 - Cohort 4: RP2D of BNT324 + BNT327 · Experimental
- Part 2 - Cohort 5: RP2D of BNT324 + BNT327 · Experimental
- Part 2 - Cohort 6: RP2D of BNT324 + BNT327 · Experimental
- Part 2 - Cohort 7: RP2D of BNT324 + BNT327 · Experimental
- Enrollment
- 594 (estimated)
- Primary outcomes
- Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose level
- Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose level
- Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose level
- Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment arm
- Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment arm
- Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment arm
- Part 2 cohorts 3-7 - ORR by cohort
- Sponsor
- BioNTech SE with DualityBio Inc.
- Start
- May 2, 2025
- Primary completion
- Sep 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06892548 · updated Aug 26, 2026